Evidence Suggests CBD Potential in Treating COVID-19

Since the start of the ongoing outbreak, the cannabis industry has been the source of some debate as stakeholders and active consumers attempt to understand COVID-19’s far-reaching effects. Pulmonologists and lung experts have cautioned that inhaled smoke from combusted plant material – be it … Read more about Evidence Suggests CBD Potential in Treating COVID-19

Amendment to NDAA Would Allow Military Service Members to Use CBD Products

A recently passed amendment to the National Defense Authorization Act (“NDAA”) could allow military service members to use cannabidiol (“CBD”) and other hemp-derived products. The measure, sponsored by veteran Rep. Tulsi Gabbard (D-HI), was introduced on July 20, 2020, and was passed in the House of … Read more about Amendment to NDAA Would Allow Military Service Members to Use CBD Products

FDA Delivers Latest CBD Study to Congress

On July 8, 2020, the U.S. Food and Drug Administration (“FDA”) delivered the results of its most comprehensive sampling study on the current cannabidiol (“CBD”) marketplace to the U.S. House Committee on Appropriations and the U.S. Senate Committee on Appropriations.1 Congress mandated FDA to … Read more about FDA Delivers Latest CBD Study to Congress

Firm Webinar: Intellectual Property and Cannabis

On May 14, The Rodman Law Group held an internal webinar to analyze the variety of intellectual property ("IP") rights available to cannabis businesses and entrepreneurs including federal and state trademark protection, patents, and copyright. Moderated by firm Associate Attorney Rebecca Spence, … Read more about Firm Webinar: Intellectual Property and Cannabis

FTC Sues Company for Unsubstantiated Claims

On April 24, 2020, the Federal Trade Commission (“FTC”) filed a complaint in federal court as well as an administrative complaint against California-based marketer, Whole Leaf Organics for its unsubstantiated product claims.1 The company sells Thrive, a supplement consisting mainly of vitamin C and … Read more about FTC Sues Company for Unsubstantiated Claims

Firm Q&A: COVID’s Impact

COVID-19 has permeated virtually every aspect of our daily society, affecting millions of people and businesses across the country, and countless others overseas. In light of the impact of COVID19 and the confusion about the various aid and stimulus packages offered by the federal government, The … Read more about Firm Q&A: COVID’s Impact

DEA Removes CBD from Controlled Substances Act

On Monday, April 6, GW Pharmaceuticals revealed that the company had received notice from the U.S. Drug Enforcement Administration (“DEA”) stating that its drug Epidiolex was no longer subject to the requirements of the Controlled Substances Act (“CSA”). In a company release announcing the agency … Read more about DEA Removes CBD from Controlled Substances Act

FDA Proposes $5 Million Budget to Regulate CBD in 2021

President Trump’s budget proposal for the 2021 fiscal year, which is set to be presented to Congress next year, should he gain re-election, includes $6.2 billion in overall funding for the Food and Drug Administration (“FDA”). This proposal includes a $5 million-line item for FDA to continue … Read more about FDA Proposes $5 Million Budget to Regulate CBD in 2021